Posted by Michael Wonder on 06 May 2021
Injectafer (ferric carboxymaltose injection) receives FDA approval for single dose option for the treatment of adult patients with iron deficiency anaemia
6 May 2021 - For patients weighing 50 kg (110 lb) or more, Injectafer may now be administered as a 1000 mg single dose for IDA treatment.
Daiichi Sankyo and American Regent today announced that the U.S. FDA has approved a single 1000 mg dose option of Injectafer (ferric carboxymaltose injection), an iron replacement product, for the treatment of iron deficiency anaemia in adult patients who have intolerance to oral iron, have had unsatisfactory response to oral iron, or have non-dialysis dependent chronic kidney disease.
